Immunization Using Polysialic Acid-KLH or N-Propionylated Polysialic Acid-KLH Conjugate Plus the Immunological Adjuvant QS-21 in Patients With Small Cell Lung Cancer Who Have Achieved a Major Response to Initial Therapy
OBJECTIVES: I. Compare the antibody response after immunization with polysialic acid keyhole
limpet hemocyanin (PSA-KLH) conjugate or N-propionylated PSA-KLH conjugate plus
immunological adjuvant QS21 in patients with small cell lung cancer. II. Assess the clinical
toxicities resulting from these regimens and from the immune response in this patient
OUTLINE: Patients receive polysialic acid keyhole limpet hemocyanin (PSA-KLH) conjugate or
N-propionylated PSA-KLH conjugate plus immunological adjuvant QS21 subcutaneously weekly on
weeks 1-4 and on weeks 8 and 16 for a total of 6 vaccinations. Patients are followed at 2
weeks, and then every 3 months for up to 1 year.
PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.
Primary Purpose: Treatment
Lee M. Krug, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|